Mellozzan[®] (melatonin) is launched in Denmark and Norway by EQL Pharma's license partner Medice Arzneimittel Pütter GmbH & Co. KG
As the first countries outside of Sweden, EQL's key product Mellozzan® has now been launched in Denmark and Norway by EQL's licensee Medice. The countries are the first in a series of seven where Medice contributes its market knowledge and network to quickly reach out with Mellozzan® to patients. In addition to Denmark and Norway, the licensee also has ongoing work for registrations and subsequent launches in Medice's home market Germany, as well as the UK, Austria, Finland and Switzerland.
"The launches of Mellozzan® in Denmark and Norway are of great importance as milestones in our ambition to reach patients outside of Sweden. In the Nordics, Europe and by extension all over the world", says EQL's CEO Axel Schörling. "We have seen the positive effects of the treatment on children with ADHD and sleep difficulties in Sweden where the use of melatonin, Mellozzan's effective substance, is today standard. We believe that the same treatment should be available to all children in the same situation regardless of geography.”
In addition to the countries covered by Medice, licensees for Mellozzan® are in various stages of registration in France, Italy, Spain, the Netherlands, Turkey and Kazakhstan. In addition, EQL has recently entered into a global license agreement with Adalvo for Mellozzan®.
About Mellozzan®
Mellozzan® contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan® is also indicated for the short-term treatment of jet lag in adults.
About EQL
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 25 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
About Medice
Medice Arzneimittel Pütter GmbH & Co. KG, founded in 1949 and headquartered in Iserlohn (Germany), is a fully integrated pharmaceutical company with own GxP capabilities in development, manufacturing and pan-European and international distribution of pharmaceuticals and medical devices. It is the core of “Medice – The Health Family” aiming to improve patient management by offering high quality innovative drugs, non-pharmacological interventions and value adding services. For more information, please visit www.medice.com.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 25 niche generics (i.e., generics with limited competition apart from the original drug) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2023 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.